Prelude Therapeutics Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase binding moiety covalently linked to a probable global ...

On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a ...

Prelude’s lead candidate, PRT3789, is a SMARCA2 degrader currently being evaluated in clinical trials. The company has completed monotherapy dose escalation and selected a Phase 2 dose, with updated ...

The updated SMARCA2 degrader data show an uptick in response rates for lung cancer at higher doses and class 1 mutations albeit on small number of patients, and the safety profile remains ...

Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.

When combined with funding from previously reported warrant exercises and ad Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple ...